328 related articles for article (PubMed ID: 23240673)
1. Molecular pathology of endometrial carcinoma.
Matias-Guiu X; Prat J
Histopathology; 2013 Jan; 62(1):111-23. PubMed ID: 23240673
[TBL] [Abstract][Full Text] [Related]
2. High concordance of molecular tumor alterations between pre-operative curettage and hysterectomy specimens in patients with endometrial carcinoma.
Stelloo E; Nout RA; Naves LC; Ter Haar NT; Creutzberg CL; Smit VT; Bosse T
Gynecol Oncol; 2014 May; 133(2):197-204. PubMed ID: 24556061
[TBL] [Abstract][Full Text] [Related]
3. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
4. Molecular approaches for classifying endometrial carcinoma.
Piulats JM; Guerra E; Gil-Martín M; Roman-Canal B; Gatius S; Sanz-Pamplona R; Velasco A; Vidal A; Matias-Guiu X
Gynecol Oncol; 2017 Apr; 145(1):200-207. PubMed ID: 28040204
[TBL] [Abstract][Full Text] [Related]
5. High-throughput interrogation of PIK3CA, PTEN, KRAS, FBXW7 and TP53 mutations in primary endometrial carcinoma.
Garcia-Dios DA; Lambrechts D; Coenegrachts L; Vandenput I; Capoen A; Webb PM; Ferguson K; ; Akslen LA; Claes B; Vergote I; Moerman P; Van Robays J; Marcickiewicz J; Salvesen HB; Spurdle AB; Amant F
Gynecol Oncol; 2013 Feb; 128(2):327-34. PubMed ID: 23219661
[TBL] [Abstract][Full Text] [Related]
6. PIK3CA mutations and amplification in endometrioid endometrial carcinomas: relation to other genetic defects and clinicopathologic status of the tumors.
Konopka B; Janiec-Jankowska A; Kwiatkowska E; Najmoła U; Bidziński M; Olszewski W; Goluda C
Hum Pathol; 2011 Nov; 42(11):1710-9. PubMed ID: 21531001
[TBL] [Abstract][Full Text] [Related]
7. Association of mammalian target of rapamycin with aggressive type II endometrial carcinomas and poor outcome: a potential target treatment.
Peiró G; Peiró FM; Ortiz-Martínez F; Planelles M; Sánchez-Tejada L; Alenda C; Ceballos S; Sánchez-Payá J; Laforga JB
Hum Pathol; 2013 Feb; 44(2):218-25. PubMed ID: 22955108
[TBL] [Abstract][Full Text] [Related]
8. Novel molecular profiles of endometrial cancer-new light through old windows.
Doll A; Abal M; Rigau M; Monge M; Gonzalez M; Demajo S; Colás E; Llauradó M; Alazzouzi H; Planagumá J; Lohmann MA; Garcia J; Castellvi S; Ramon y Cajal J; Gil-Moreno A; Xercavins J; Alameda F; Reventós J
J Steroid Biochem Mol Biol; 2008 Feb; 108(3-5):221-9. PubMed ID: 18061438
[TBL] [Abstract][Full Text] [Related]
9. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
[TBL] [Abstract][Full Text] [Related]
10. Endometrial carcinoma: pathology and genetics.
Prat J; Gallardo A; Cuatrecasas M; Catasús L
Pathology; 2007 Feb; 39(1):72-87. PubMed ID: 17365824
[TBL] [Abstract][Full Text] [Related]
11. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors.
Abal M; Planaguma J; Gil-Moreno A; Monge M; Gonzalez M; Baro T; Garcia A; Castellvi J; Ramon Y Cajal S; Xercavins J; Alameda F; Reventos J
Histol Histopathol; 2006 Feb; 21(2):197-204. PubMed ID: 16329044
[TBL] [Abstract][Full Text] [Related]
12. Endometrial carcinoma: molecular alterations involved in tumor development and progression.
Yeramian A; Moreno-Bueno G; Dolcet X; Catasus L; Abal M; Colas E; Reventos J; Palacios J; Prat J; Matias-Guiu X
Oncogene; 2013 Jan; 32(4):403-13. PubMed ID: 22430211
[TBL] [Abstract][Full Text] [Related]
13. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis.
Koul A; Willén R; Bendahl PO; Nilbert M; Borg A
Cancer; 2002 May; 94(9):2369-79. PubMed ID: 12015762
[TBL] [Abstract][Full Text] [Related]
14. Pathology of Endometrial Carcinoma.
Lax SF
Adv Exp Med Biol; 2017; 943():75-96. PubMed ID: 27910065
[TBL] [Abstract][Full Text] [Related]
15. High frequency of POLE mutations in synchronous endometrial and ovarian carcinoma.
Ishikawa M; Nakayama K; Nakamura K; Ono R; Yamashita H; Ishibashi T; Minamoto T; Iida K; Razia S; Ishikawa N; Kyo S
Hum Pathol; 2019 Mar; 85():92-100. PubMed ID: 30448219
[TBL] [Abstract][Full Text] [Related]
16. Molecular genetic characterization of tamoxifen-associated endometrial cancer.
Prasad M; Wang H; Douglas W; Barakat RR; Ellenson LH
Gynecol Oncol; 2005 Jan; 96(1):25-31. PubMed ID: 15589576
[TBL] [Abstract][Full Text] [Related]
17. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
[TBL] [Abstract][Full Text] [Related]
19. Pathology of endometrioid carcinoma.
Albertini AF; Devouassoux-Shisheboran M; Genestie C
Bull Cancer; 2012 Jan; 99(1):7-12. PubMed ID: 22231875
[TBL] [Abstract][Full Text] [Related]
20. Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.
Turbiner J; Moreno-Bueno G; Dahiya S; Sánchez-Estevez C; Hardisson D; Prat J; Oliva E; Palacios J
Mod Pathol; 2008 Aug; 21(8):925-36. PubMed ID: 18500270
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]